BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72 [PMID: 29147645 DOI: 10.5501/wjv.v6.i4.59]
URL: https://www.wjgnet.com/2220-3249/full/v6/i4/59.htm
Number Citing Articles
1
Eiji Mita, Lauren J. Liu, Danielle Shing, Lindsey Force, Kouji Aoki, Daisuke Nakamoto, Akinobu Ishizaki, Hiroki Konishi, Hajime Mizutani, Leslie J. Ng. Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in JapanInternal Medicine 2022;  doi: 10.2169/internalmedicine.0067-22
2
Michael E. Porter, Thomas H. Lee, Alice C. A. Murray. The Value-Based Geography Model of CareNEJM Catalyst 2020; 1(2) doi: 10.1056/CAT.19.1130